In vivo continuous glucose monitoring has posed a significant challenge to glucose sensor development due to the lack of reliable techniques that are non- or at least minimally-invasive. In this proof-of-concept study, we demonstrated the development of a new glucose sensor protein, AcGFP1-GBPcys-mCherry, and an optical sensor assembly, capable of generating quantifiable FRET (fluorescence resonance energy transfer) signals for glucose monitoring. Our experimental data showed that the engineered glucose sensor protein can generate measurable FRET signals in response to glucose concentrations varying from 25 to 800 μM. The sensor developed based on this protein had a shelf-life of up to 3 weeks. The sensor response was devoid of interference from compounds like galactose, fructose, lactose, mannose, and mannitol when tested at physiologically significant concentrations of these compounds. This new glucose sensor protein can potentially be used to develop implantable glucose sensors for continuous glucose monitoring.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997158 | PMC |
http://dx.doi.org/10.1016/j.bios.2010.08.052 | DOI Listing |
Mikrochim Acta
January 2025
Indian Institute of Technology (BHU), Varanasi, 221005, India.
In the modern age, half of the population is facing various chronic illnesses due to glucose maintenance in the body, major causes of fatality and inefficiency. The early identification of glucose plays a crucial role in medical treatment and the food industry, particularly in diabetes diagnosis. In the past few years, non-enzymatic electrochemical glucose sensors have received a lot of interest for their ability to identify glucose levels accurately.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Electrical Engineering, Feng Chia University, Taichung, 407802, Taiwan.
This study presents an innovative glucose detection platform, featuring a highly sensitive, non-enzymatic glucose sensor. The sensor integrates nickel nanowires and a graphene thin film deposited on the gate region of an extended-gate electric double-layer field-effect transistor (EGEDL-FET). This unique combination of materials and device structure enables superior glucose sensing performance.
View Article and Find Full Text PDFDiabetol Int
January 2025
Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541 Japan.
Unlabelled: The hybrid closed-loop (HCL) system, Medtronic MiniMed 770G, has been available for use by Japanese individuals with type 1 diabetes mellitus since 2021. The aim of this study was to evaluate the effect of its use on glycemic variability and quality of life (QOL) in this population. This multicenter, open-label, prospective observational study included 14 Japanese individuals with type 1 diabetes mellitus treated with MiniMed 640G.
View Article and Find Full Text PDFMech Ageing Dev
January 2025
Department of Biological Science, College of Natural Science, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Republic of Korea; BK21 FOUR Education Research Group for Age-Associated Disorder Control Technology, Department of Integrative Biological Science, Chosun University, Gwangju 61452, Republic of Korea; The Basic Science Institute of Chosun University, Chosun University, Gwangju 61452, Republic of Korea. Electronic address:
The protective effects of mangiferin (MAG) against etoposide- and high glucose (HG)-induced DNA damage and aging were investigated in human bone marrow-mesenchymal stem cells (hBM-MSCs). Etoposide, a topoisomerase II inhibitor, was used to induce double-strand breaks (DSBs) in hBM-MSCs, resulting in increased genotoxicity, elevated levels of the DNA damage sensor ATM and CDKN1A, and decreased levels of the aging markers H3 and H4. MAG activated AMPK and SIRT1, thus protecting against DSB-induced damage.
View Article and Find Full Text PDFDiabetes Technol Ther
January 2025
Senseonics, Incorporated, Germantown, Maryland, USA.
The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!